Clinical Trial

Clinical Trial to Evaluate the Protective Efficacy and Safety of a Nasal Spray Live Attenuated Influenza Vaccine (LAIV) in Adults Aged 18-59 Years Post-Vaccination

Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated August 21, 2025 (before its estimated March 2026 completion). Its status may not reflect the trial's current state.
Summary
A Clinical Trial to Evaluate the Protective Efficacy and Safety of a Nasal Spray Live Attenuated Influenza Vaccine (LAIV) in Adults Aged 18-59 Years Post-Vaccination
Trial Details
NCT Number NCT07133802
Lead Sponsor Changchun BCHT Biotechnology Co.
Collaborators: Hebei Provincial Center for Disease Control and Prevention, Center for Disease Control and Prevention, Fujian, Zhejiang Provincial Center for Disease Control and Prevention
Conditions Prevention of Influenza
Enrollment 6,680 participants
Start Date 2025-08
Primary Completion 2026-03 (estimated)
Study Completion 2026-07 (estimated)
Updated on ClinicalTrials.gov 2025-08-21